Aptose Biosciences Inc trades with the ticker APS on the TSX and is in the Biotechnology industry.
Overview
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Looking to invest in Aptose Biosciences Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
APS.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $33.927MM
PE Ratio:
Price: 2.09 (Updated: 3/12/2024 0:47:16)
Aptose Biosciences Inc (APS) vs Competitors in Biotechnology
Lets see how APS.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc, Intellipharmaceutics International Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- Aptose Biosciences Inc (APS) vs Aeterna Zentaris Inc (AEZS)
- AEZS has higher EPS (-6.47 vs -10.45). AEZS and APS both have P/E’s under 0.
- Aptose Biosciences Inc (APS) vs BELLUS Health Inc (BLU)
- BLU has higher EPS (-0.96 vs -10.45). BLU provides dividends, while APS does not. BLU and APS both have P/E’s under 0.
- Aptose Biosciences Inc (APS) vs Fennec Pharmaceuticals Inc (FRX)
- FRX has higher EPS (-1.01 vs -10.45). FRX and APS both have P/E’s under 0.
- Aptose Biosciences Inc (APS) vs IMV Inc (IMV)
- IMV has higher EPS (-6.11 vs -10.45). IMV provides dividends, while APS does not. IMV and APS both have P/E’s under 0.
- Aptose Biosciences Inc (APS) vs Intellipharmaceutics International Inc (IPCI)
- IPCI has higher EPS (-0.12 vs -10.45). IPCI and APS both have P/E’s under 0.
Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability.
How to Buy APS stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
